Overexpression of STC2 has been demonstrated to contribute to poor prognosis or recurrence in colorectal (15), gastric (16) and prostate (17) cancer, as well as neuroblastoma (18) and renal cell carcinoma (8). This evidence concerns the gene STC2 and medical procedure.